Edward Nash
Stock Analyst at Canaccord Genuity
(2.05)
# 1,559
Out of 4,412 analysts
51
Total ratings
30.77%
Success rate
-1.86%
Average return
Main Sectors:
Top Industries:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Maintains: Buy | $12 → $20 | $3.25 | +515.38% | 2 | Apr 8, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $21 → $9 | $6.68 | +34.73% | 1 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $338 → $377 | $193.33 | +95.00% | 6 | Mar 15, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $16 → $15 | $3.93 | +281.68% | 5 | Mar 13, 2024 | |
| MORF Morphic Holding | Maintains: Buy | $68 → $66 | $28.07 | +135.13% | 2 | Mar 8, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $37 → $38 | $22.80 | +66.67% | 3 | Dec 13, 2023 | |
| VRNA Verona Pharma | Reiterates: Buy | $35 | $15.47 | +126.24% | 4 | Sep 1, 2023 | |
| TVTX Travere Therapeutics | Maintains: Buy | $37 → $35 | $5.26 | +565.40% | 5 | Jul 18, 2023 | |
| THTX Theratechnologies | Assumes: Hold | $8 | $1.32 | +506.06% | 3 | Jul 3, 2023 | |
| RZLT Rezolute | Maintains: Buy | $16 → $17 | $2.66 | +539.10% | 2 | May 19, 2023 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $5 → $6 | $1.78 | +237.08% | 2 | May 19, 2023 | |
| PLRX Pliant Therapeutics | Initiates: Buy | $48 | $11.81 | +306.44% | 1 | May 18, 2023 | |
| AKRO Akero Therapeutics | Maintains: Buy | $58 → $59 | $19.74 | +198.89% | 3 | May 17, 2023 | |
| ORMP Oramed Pharmaceuticals | Maintains: Hold | $3 → $2 | $2.46 | -18.70% | 3 | May 17, 2023 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | $75 → $15 | $0.39 | +3,730.44% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Maintains: Hold | $120 → $80 | $9.19 | +770.51% | 3 | Sep 13, 2019 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | n/a | $44.24 | - | 3 | Oct 29, 2018 | |
| QURE uniQure | Initiates: Buy | n/a | $4.53 | - | 1 | May 24, 2018 | |
| ABEO Abeona Therapeutics | Initiates: Buy | n/a | $3.26 | - | 1 | Nov 8, 2017 |
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.25
Upside: +515.38%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21 → $9
Current: $6.68
Upside: +34.73%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $193.33
Upside: +95.00%
Ventyx Biosciences
Mar 13, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $3.93
Upside: +281.68%
Morphic Holding
Mar 8, 2024
Maintains: Buy
Price Target: $68 → $66
Current: $28.07
Upside: +135.13%
Corcept Therapeutics
Dec 13, 2023
Maintains: Buy
Price Target: $37 → $38
Current: $22.80
Upside: +66.67%
Verona Pharma
Sep 1, 2023
Reiterates: Buy
Price Target: $35
Current: $15.47
Upside: +126.24%
Travere Therapeutics
Jul 18, 2023
Maintains: Buy
Price Target: $37 → $35
Current: $5.26
Upside: +565.40%
Theratechnologies
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.32
Upside: +506.06%
Rezolute
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $2.66
Upside: +539.10%
Cardiol Therapeutics
May 19, 2023
Maintains: Buy
Price Target: $5 → $6
Current: $1.78
Upside: +237.08%
Pliant Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $48
Current: $11.81
Upside: +306.44%
Akero Therapeutics
May 17, 2023
Maintains: Buy
Price Target: $58 → $59
Current: $19.74
Upside: +198.89%
Oramed Pharmaceuticals
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.46
Upside: -18.70%
Galmed Pharmaceuticals
Aug 8, 2022
Downgrades: Hold
Price Target: $75 → $15
Current: $0.39
Upside: +3,730.44%
Adverum Biotechnologies
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $9.19
Upside: +770.51%
Ultragenyx Pharmaceutical
Oct 29, 2018
Maintains: Buy
Price Target: n/a
Current: $44.24
Upside: -
uniQure
May 24, 2018
Initiates: Buy
Price Target: n/a
Current: $4.53
Upside: -
Abeona Therapeutics
Nov 8, 2017
Initiates: Buy
Price Target: n/a
Current: $3.26
Upside: -